Sign inJoin waitlistJoin the waitlist

Yucai Wang

Associate Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2016–2019
Cancer Genetics The University of Texas MD Anderson Cancer Center
Internal Medicine
Rutgers New Jersey Medical School
2013–2016
- Clinical Medicine Nanjing University School of Medicine
2001–2005

Research

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2019 · First of 19 authors · 739 citations
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Review · Journal of Oncology Practice · 2018 · 362 citations
Molybdenum derived from nanomaterials incorporates into molybdenum enzymes and affects their activities in vivo
Nature Nanotechnology · 2021 · 181 citations

Stephen Ansell
57 papers
Thomas Habermann
57 papers
GN
Grzegorz Nowakowski
51 papers
Thomas Witzig
42 papers
Jonas Paludo
38 papers
Patrick Johnston
37 papers
Sameer Parikh
32 papers
YL
Yi Lin
29 papers
Arushi Khurana
28 papers
JM
Javier Munoz
27 papers
Neil Kay
27 papers
Paul Hampel
27 papers · 8 as a fellow

Clinical trials

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Recruiting · Phase 2
Academic and Community Cancer Research United
2024–2030
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
2023–2030
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Principal investigator · Active not recruiting · Phase 1
Mayo Clinic
2020–2028
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032